Sichuan Kelun Pharmaceutical Co., Ltd. (hereinafter referred to as "the Company") announces the issuance results of the third phase of technology innovation bonds for 2026.
The Company and the board of directors confirm that the contents of this announcement are true, accurate, and complete, without any false statements or material omissions.